NVX revenueFY2025$5.62M
- FY YoY
- -4.1%
NVX revenue was $5.62M for fiscal 2025 (ended Dec 31, 2025), down 4.1% from fiscal 2024.
For fiscal 2025 (ended Dec 31, 2025), NOVONIX Limited reported $5.62M of revenue and -$92.73M of net income.
NVX revenue was $5.62M for fiscal 2025 (ended Dec 31, 2025), down 4.1% from fiscal 2024.
NVX net income was -$92.73M for fiscal 2025 (ended Dec 31, 2025), compared with -$74.82M in fiscal 2024.
NVX diluted EPS was -$0.14 for fiscal 2025 (ended Dec 31, 2025), compared with -$0.15 in fiscal 2024.
NVX free cash flow was -$102.37M for fiscal 2025 (ended Dec 31, 2025), compared with -$70.30M in fiscal 2024.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 |
|---|---|---|---|---|---|---|
| Revenue | $5.62M | $5.85M | $8.05M | $6.10M | $3.89M | $2.85M |
| Research and development | $5.67M | $4.85M | $5.75M | $5.10M | $2.09M | $1.62M |
| Operating income | $276.14M | $150.82M | - | - | - | - |
| Pre-tax income | -$92.70M | -$74.72M | -$46.45M | -$51.86M | -$13.45M | -$13.43M |
| Income tax | $25.5K | $97.7K | -$199.9K | $0 | $0 | $0 |
| Net income | -$92.73M | -$74.82M | -$46.25M | -$51.86M | -$13.45M | -$13.43M |
| EPS, basic | -$0.14 | -$0.15 | -$0.09 | -$0.11 | -$0.04 | -$0.10 |
| EPS, diluted | -$0.14 | -$0.15 | -$0.09 | -$0.11 | -$0.04 | -$0.10 |
| Diluted shares | 681.7M | 496.9M | 487.5M | 464.4M | 366.3M | 135.9M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $79.87M | $42.56M | $78.71M | $142.74M | $102.60M | $26.69M |
| Receivables | $2.12M | $8.16M | $3.56M | $2.45M | $1.63M | $739.6K |
| Inventory | $2.18M | $1.38M | $2.00M | $1.87M | $2.09M | $940.2K |
| Current assets | $89.16M | $57.30M | $89.15M | $162.22M | $108.23M | $28.47M |
| Goodwill | $11.98M | $11.98M | $11.98M | $11.98M | $11.98M | $11.98M |
| Total assets | $282.92M | $226.10M | $263.34M | $302.98M | $152.31M | $51.76M |
| Current liabilities | $83.56M | $46.24M | $37.26M | $7.89M | $4.02M | $3.99M |
| Long-term debt | $31.78M | $32.78M | $34.67M | $35.95M | $4.49M | $1.33M |
| Total debt | $31.78M | $32.78M | $34.67M | $35.95M | $4.49M | $1.33M |
| Total liabilities | $121.25M | $88.51M | $79.41M | $51.85M | $13.86M | $7.23M |
| Shareholders' equity | $161.67M | $137.59M | $183.94M | $251.13M | $138.45M | $44.53M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$42.20M | -$40.42M | -$36.23M | -$29.23M | -$6.09M | -$3.75M |
| Capital expenditures | $60.17M | $29.88M | $19.18M | $83.69M | $19.49M | $3.58M |
| Free cash flow | -$102.37M | -$70.30M | -$55.41M | -$112.92M | -$25.58M | -$7.33M |
| Investing cash flow | -$32.86M | -$18.17M | -$11.74M | -$106.80M | -$19.68M | -$3.69M |
| Financing cash flow | $109.90M | $25.21M | $29.31M | $180.69M | $103.77M | $30.48M |
| Stock-based compensation | -$1.13M | $5.52M | $5.62M | $14.68M | $4.47M | $5.07M |
| Depreciation and amortization | $4.57M | $4.57M | $4.74M | $4.21M | $1.26M | $1.18M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 |
|---|---|---|---|---|---|---|
| Revenue growth, YoY | -4.1% | -27.3% | 32.0% | 56.7% | 36.6% | - |
| Operating margin | 4916.0% | 2576.2% | - | - | - | - |
| Net margin | -1650.8% | -1278.0% | -574.2% | -850.0% | -345.3% | -471.1% |
| Free cash flow margin | -1822.5% | -1200.8% | -687.9% | -1850.8% | -656.9% | -257.0% |
| Return on equity | -57.4% | -54.4% | -25.1% | -20.7% | -9.7% | -30.2% |
| Return on assets | -32.8% | -33.1% | -17.6% | -17.1% | -8.8% | -25.9% |
| Current ratio | 1.07 | 1.24 | 2.39 | 20.56 | 26.92 | 7.14 |
| Debt to equity | 0.20 | 0.24 | 0.19 | 0.14 | 0.03 | 0.03 |
Source: XBRL data NOVONIX Limited files with the SEC, latest filing dated Feb 26, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| NVX | $5.62M | -4.1% | -$92.73M | -1650.8% | $46.9M |
| ASML | €32.67B | +15.6% | €9.61B | 29.4% | $583.23B |
| LRCX | $26.13B | +33.4% | $8.45B | 32.3% | $276.45B |
| TMO | $47.35B | +8.3% | $7.07B | 14.9% | $267.38B |
| DE | $47.98B | +8.0% | $4.87B | 10.2% | $186.39B |
| DHR | $25.61B | +5.5% | $4.33B | 16.9% | $165.41B |
| ETN | $31.98B | +20.1% | $3.90B | 12.2% | $139.59B |
| JCI | $24.43B | +5.1% | $3.53B | 14.5% | $85.71B |
| ITW | $16.65B | +4.8% | $3.23B | 19.4% | $81.49B |